Monday, 24 April 2017

ACP-196 (Acalabrutinib) - BTK Inhibitor

Has anyone had experience with this trial drug for glioblastoma?  My wife was just diagnosed with second recurrence and this trial may become an option soon. She is grade 4 GBM for 20 months now. Has had two surgeries, radiation, temozolomide. She is MGMT negative and IDH-wild. She was set to start next cycle of maintenance Temozolomide when we got the MRI results. We have to make a new chemo treatment decision as soon as possible. Thank you for anyone who has had any experience with ACP-196.


  1. Although Bruton's tyrosine kinase (the target of drugs like this one) does have some evidence as a valid target for GBM, I have no reason to believe this drug as a single agent will be any more effective than any other kinase inhibitor that has been tried and failed as a single agent therapy for recurrrent GBM. This is why this blog exists, because single agent therapies are so often ineffective, even when there is some preclinical evidence suggesting the drug could be useful.
    Preclinical investigation of ibrutinib, a Bruton’s kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes

    1. Where are you located? There may be better trial options out there for her.